Tada

I agree with your post and reading between the lines I would expect to see an announcement on BOM2 soon.

I have some questions - 

your post is the first time I read that apabetalone had an NNT of 30. How good is that NNT. I read one example that cited Lipitor as having an NNT of 100. If apabetalone has an NNT relative to MACE of 30 - how good is that? Do you happen to know the NNT of Entresto?

In my opinion, Entresto may be the reason for RVX-208 not initially garnering recognition in the medical community. I believe Entresto was a BTD and received mid-trial approval from the FDA. Approval occurred during the BOM trial. Entresto treats heart failure and low ejection fraction and has a blockbuster market of 3B per year.

The secondary endpoints in the BOM trial re:kidney patients treated with apebetalone in combination with new oral anti-diabetic treatments is huge since known risks taking Entresto are renal failure and impairment and hypotension. Diabetic patients will now have an alternative.

There is a lot going on

Chicagoest